Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc. will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis.

AstraZeneca topped the first annual Pharmaceutical Invention Index, released by IDEA Pharma.

Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital launched a joint laboratory to research new drugs to treat chronic lung diseases.

Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD.

AstraZeneca Plc stopped a mid-stage study for testing partner Synairgen Plc’s drug candidate as a potential treatment for severe asthma.

Merck & Co. is acquiring Afferent Pharmaceuticals for an upfront cash payout of $500 million of stock and an additional $750 million based on various clinical and commercial milestones.

Drugmaker Bristol-Myers Squibb said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring. The deal gives Bristol-Myers access to Promedior Inc’s lead experimental drug, PRM-151, which is being tested to treat two types of fibrosis. PRM-151 is […]

SYDNEY and SOUTHAMPTON, England, Aug. 5, 2015 /PRNewswire/ — Australian pharmaceutical company Pharmaxis Ltd (ASX: PXS) and UK biotechnology company Synairgen plc (LSE: SNG) today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF). […]